Market LIVE
Published markets; coverage varies by country
Product profile · United States

ABSTRAL

 ·  Patent Litigation & Settlement History ↓

IngredientFENTANYL CITRATE
Application typeNDA
Application022510
Product003
Dosage formTABLET
RouteSUBLINGUAL
StrengthEQ 0.3MG BASE
Approval date2011-01-07
Marketing statusDiscontinued
Status event—
ApplicantSENTYNL THERAPS INC
Product source

Current GenericRadar decision

Year—
SelectionDISCONTINUED
ReviewFINAL_CHECKING
Anchor typeTERMINAL_MARKETING_STATUS
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date2019-09-24
First Final ANDA—
Status event—

FDA_DISCONTINUED_MARKETING_STATUS. Actual discontinuation date/year not established; do not substitute approval or review date. Store underlying canonical rights separately.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US67590592019-09-24DP/U U-767NNDP
Sublingual fentanyl carrier/mucoadhesive composition. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.
———
US67619102019-09-24DP/U U-767NNDP
Water-free sublingual active-particle/carrier composition. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.
———
US79101322019-09-24DP/U U-767NNDP_U
Sublingual fentanyl breakthrough-pain method with particle, adhesion and rapid-delivery requirements. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-12 · NO_REGULATORY_EXCLUSIVITY_IDENTIFIED · Historical coverage: ANNUALS_2011_2026_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (4)
TypeDateRoleBasisSource
PATENT2019-09-24FTO_TAILSublingual fentanyl carrier/mucoadhesive composition. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.Source
PATENT2019-09-24FTO_TAILSublingual fentanyl breakthrough-pain method with particle, adhesion and rapid-delivery requirements. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.Source
PATENT2019-09-24FTO_TAILWater-free sublingual active-particle/carrier composition. Full product scope is not established by the retrieved claims and product evidence; no DS-equivalent promotion is made.Source
REGULATORY_STATUS—TERMINAL_STATUSFDA_DISCONTINUED_MARKETING_STATUS. Actual discontinuation date/year not established; do not substitute approval or review date. Store underlying canonical rights separately.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.